The management of non-alcoholic steatohepatitis (NASH) has witnessed unprecedented transformation with Madrigal Pharmaceuticals' revolutionary introduction of Rezdiffra (resmetirom), creating a paradigmatic shift in specialized hepatic therapeutics. This groundbreaking medication establishes the remarkable distinction of being the first FDA-sanctioned treatment specifically engineered to combat...